Abstract 3581
Background
Ageing is a global phenomenon and has huge impact in healthcare. Still emerging in developing nations, there has been no major national innitiative focusing on oncologic geriatric patients (pts). The study describes a program to > 70y cancer pts in A C Camargo Cancer Center. We hypothesized that incorporating CGA into daily practice can improve individualized care.
Methods
Previous aims were to evaluate if: 1) CGA could be feasible in daily practice; 2) it could be useful as a tool in treatment/tx decision making; 3) analyse the impact of CGA in the selection of tx, with its ability to predict complications (such as dosis reduction, hospitalization, or tx discontinuation) in an Oncogeriatric Unit. The present study is to present the long term survival of those pts, candidates to receive systemic tx, who underwent CGA assessments, which included scales of: ADL (Katz, Lawton), mini-nutritional assessment, depression (GDS), comorbidities and polypharmacy. Patients were classified as fit, borderline or frail. Fit pts received mainly full treatment; frail/borderline pts, mainly modified tx or specific supportive care.
Results
From Oct 25/10-Dec/12/12, 638 pts were included to be prospectively evaluated - female 55%; cancers (%): breast 26, prostate 12, colorectal 12, hematologic 8. Katz A = 68%, Lawton 27=45%; polipharmacy ( > =5): 48%; depression 29%, undernutrition: 21%. We have previously presented (ASCO 2014) that there was an association between the choice of oncologic treatment (original vs modified or with additional dose reduction) with Katz, Lawton, depression and nutrition scales (p < =0.035); as well as the ability to complete the individualized proposed treatment, which was correlated with Lawton (p = 0.04) scale. Hospitalization during chemotherapy was associated with comorbidities, altered Katz, Lawton and depression scales (p < =0.038). With 610 pts evaluable, median survival was 51.7 months.
Conclusions
We could find a high long term survival of 70+ cancer pts, showing CGA to be feasible and allowing long term survival follow-up. However, many pts have been lost to follow-up. How to better perform in pts' adherence and to reduce bias must be a concern in real world geriatric oncology.
Clinical trial identification
Legal entity responsible for the study
Aldo L.A. Dettino; Grupo de Assistencia, Ensino e Pesquisa em Oncologia (GAEPO).
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1449 - Prognostic factors associated with pathological complete response in early breast cancer patients undergoing neoadjuvant chemotherapy. The importance of Ki-67 and molecular subtype.
Presenter: Bernardo Rapoport
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4023 - The accuracy of sentinel lymph node biopsy following neoadjuvant chemotherapy in clinically node positive breast cancer patients: A single institution experience
Presenter: Narges Sistany Allahabadi
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4707 - Index BRCA1/2 testing under a multidisciplinary program
Presenter: Duarte Machado
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3393 - BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients
Presenter: Alex Friedlaender
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3175 - PALB2 germ-line mutations in Russian breast cancer patients: identification of recurrent alleles and analysis of phenotypic characteristics of the tumors
Presenter: Evgeny Imyanitov
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3027 - Landscape of germline mutations in hereditary breast and ovarian cancer (HBOC) patients in Russia revealed by target panel sequencing
Presenter: Elena Shagimardanova
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4963 - Lynch syndrome-associated hereditary mutations cause breast and ovarian cancer: results from Russian Heredetary Oncogenomics project
Presenter: Marat Gordiev
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2916 - Impact of deleterious germline BRCA mutations, addition of taxanes and use of adjuvant endocrine therapy (ET) on anti-müllerian hormone (AMH) levels in early breast cancer (EBC) patients treated by adjuvant chemotherapy (CT)
Presenter: Nathalie OLYMPIOS
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2400 - Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study
Presenter: Esther Pohl
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
1345 - BRCA1/BRCA2 Predictive Genetic Testing in an Irish Population: A Missed Opportunity
Presenter: David O Reilly
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract